<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Congenital anomalies: Causes</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Congenital anomalies: Causes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Congenital anomalies: Causes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carlos A Bacino, MD, FACMG</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen V Firth, DM, FRCP, FMedSci</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Louise Wilkins-Haug, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H262967895"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A congenital anomaly refers to an anatomic structural anomaly present at birth. These defects can be caused by genetic abnormalities and/or environmental exposures, although the underlying etiology is often unknown [<a href="#rid1">1</a>]. Congenital anomalies can be isolated or present in a characteristic combination or pattern that may affect one or more organ systems. What is, then, a genetic disorder? It is an abnormality caused by a change or pathogenic variant in the genome that often leads to medical consequences. Even though most genetic disorders are congenital, they may have a delayed clinical presentation or adult onset. These disorders can be inherited or the result of a new pathogenic variant.</p><p>This topic discusses the causes of congenital anomalies. The epidemiology, types, patterns, and evaluation of congenital anomalies are discussed in detail separately, as well as the specific congenital anomalies. (See  <a class="medical medical_review" href="/z/d/html/110898.html" rel="external">"Congenital anomalies: Epidemiology, types, and patterns"</a> and  <a class="medical medical_review" href="/z/d/html/2940.html" rel="external">"Congenital anomalies: Approach to evaluation"</a>.)</p><p class="headingAnchor" id="H251793790"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>The causes of congenital anomalies are genetic and nongenetic [<a href="#rid2">2</a>].</p><p>Genetic abnormalities include:</p><p class="bulletIndent1"><span class="glyph">●</span>Chromosomal disorders (eg, Down syndrome). (See  <a class="medical medical_review" href="/z/d/html/426.html" rel="external">"Down syndrome: Overview of prenatal screening"</a> and  <a class="medical medical_review" href="/z/d/html/2917.html" rel="external">"Down syndrome: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Single-gene (monogenic) disorders are disorders that present with different modes of inheritance including autosomal recessive, autosomal dominant, or X-linked disorders. The following are examples of single-gene disorders causing limb malformations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autosomal dominant (eg, ectrodactyly, ectodermal dysplasia, cleft lip, and cleft palate [EEC]). Dominant pathogenic variants in the p63 gene are associated with EEC and other related syndromes [<a href="#rid3">3,4</a>]. Ectrodactyly is a major limb malformation characterized by absence or underdevelopment of central metacarpals and/or metatarsals leading to a so-called split hand/foot deformity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autosomal recessive (eg, some forms of Adams-Oliver syndrome). This rare disorder is characterized by limb reduction defects (limb hypoplasia, absent digits, absent feet, syndactyly) often seen in association with cutis aplasia of the scalp. Although autosomal dominant forms are more common, this syndrome may be caused by pathogenic variants in recessive genes such as the dedicator of cytokinesis 6 (<em>DOCK6</em>)<em> </em>gene [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>X linked (eg, focal dermal hypoplasia or Goltz syndrome). This syndrome is caused by pathogenic variants in the protein-serine O-palmitoleoyltransferase porcupine homolog (<em>PORCN</em>) gene at Xp11.23, which lead to severe limb malformations (absent digits, polydactyly, syndactyly) as well as cutaneous-dermal defects with fat herniation [<a href="#rid6">6,7</a>].</p><p></p><p>Nongenetic teratogenic etiologies include:</p><p class="bulletIndent1"><span class="glyph">●</span>Maternal phenylketonuria (PKU) or diabetes (see <a class="local">'Maternal illnesses'</a> below and  <a class="medical medical_review" href="/z/d/html/2919.html" rel="external">"Overview of phenylketonuria", section on 'Phenylalanine embryopathy (maternal PKU)'</a> and  <a class="medical medical_review" href="/z/d/html/5058.html" rel="external">"Infants of mothers with diabetes (IMD)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drugs and chemical agents (eg, alcohol, oral <a class="drug drug_pediatric" data-topicid="13395" href="/z/d/drug information/13395.html" rel="external">isotretinoin</a>) (see <a class="local">'Drug exposure'</a> below and <a class="local">'Chemical agents'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infections during the prenatal period (cytomegalovirus [CMV], rubella, Zika virus) (see <a class="local">'Infectious agents'</a> below and  <a class="medical medical_review" href="/z/d/html/6011.html" rel="external">"Overview of TORCH infections"</a> and  <a class="medical medical_review" href="/z/d/html/107211.html" rel="external">"Zika virus infection: Evaluation and management of pregnant patients"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fetal crowding due to multiple gestations (see  <a class="medical medical_review" href="/z/d/html/4998.html" rel="external">"Neonatal complications of multiple births", section on 'Congenital anomalies'</a>)</p><p></p><p>Multifactorial disorders are conditions that result from the interaction of multiple genes and environmental factors. They include:</p><p class="bulletIndent1"><span class="glyph">●</span>Nonsyndromic cleft lip/palate (see  <a class="medical medical_review" href="/z/d/html/6769.html" rel="external">"Etiology, prenatal diagnosis, obstetric management, and recurrence of cleft lip and/or palate"</a> and  <a class="medical medical_review" href="/z/d/html/2920.html" rel="external">"Overview of craniofacial clefts and holoprosencephaly"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonsyndromic congenital heart disease (see  <a class="medical medical_review" href="/z/d/html/6755.html" rel="external">"Congenital heart disease: Prenatal screening, diagnosis, and management"</a> and  <a class="medical medical_review" href="/z/d/html/5780.html" rel="external">"Cardiac causes of cyanosis in the newborn"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neural tube defects (see  <a class="medical medical_review" href="/z/d/html/460.html" rel="external">"Neural tube defects: Overview of prenatal screening, evaluation, and pregnancy management"</a>)</p><p></p><p class="headingAnchor" id="H3095965732"><span class="h1">GENETIC ABNORMALITIES</span><span class="headingEndMark"> — </span>Genetic abnormalities can range from a point mutation in a single gene disrupting developmental pathways or proteins, to the presence of additional or missing chromosomal material (copy number variation) that can affect from a small segment to an entire chromosome. (See  <a class="medical medical_review" href="/z/d/html/2900.html" rel="external">"Basic genetics concepts: DNA regulation and gene expression", section on 'Genetic variation'</a>.)</p><p class="headingAnchor" id="H181408943"><span class="h2">Chromosomal disorders</span><span class="headingEndMark"> — </span>Chromosomal aberrations are due to a change in the normal chromosome number (aneuploidies) or a change in the structure of a chromosome (sizable deletions, microdeletions, duplications, translocations, and inversions).</p><p>The syndromes caused by congenital aneuploidies have several common characteristics:</p><p class="bulletIndent1"><span class="glyph">●</span>More than 90 percent of embryos/fetuses with congenital chromosomal abnormalities do not survive to term. In trisomy 21, for example, 40 percent of fetuses are lost after 12 weeks of gestation. Even higher embryonic and fetal loss rates are found with monosomy X (45,X or Turner syndrome) [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple organ systems tend to be involved, especially the central nervous system (CNS). Intellectual disability, in particular, is a common abnormality in viable infants with chromosome disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The longevity and fertility of persons with these aneuploidies and other chromosomal disorders tend to be reduced. That also includes carriers of balanced chromosome translocations.</p><p></p><p>Congenital chromosomal disorders are reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/452.html" rel="external">"Congenital cytogenetic abnormalities"</a> and  <a class="medical medical_review" href="/z/d/html/16974.html" rel="external">"Sex chromosome abnormalities"</a> and  <a class="medical medical_review" href="/z/d/html/4490.html" rel="external">"Chromosomal translocations, deletions, and inversions"</a> and  <a class="medical medical_review" href="/z/d/html/16660.html" rel="external">"Microdeletion syndromes (chromosomes 1 to 11)"</a> and  <a class="medical medical_review" href="/z/d/html/16648.html" rel="external">"Microdeletion syndromes (chromosomes 12 to 22)"</a> and  <a class="medical medical_review" href="/z/d/html/13557.html" rel="external">"Microduplication syndromes"</a>.)</p><p class="headingAnchor" id="H1362247184"><span class="h2">Disorders due to single-gene defects</span><span class="headingEndMark"> — </span>There is a wide range of congenital anomalies caused by single-gene defects. These defects encompass point mutations (pathogenic variants) and intragenic changes causing small insertions or deletions (indels), leading to disruption of gene transcription and protein synthesis. Current nomenclature changes have replaced the use of the term "mutations" with "pathogenic variants." The pattern of inheritance may be autosomal dominant, autosomal recessive, or sex linked. A single defect in a gene on an autosome (not a sex X or Y chromosome) may cause a disorder with autosomal dominant inheritance. In this case, the patient is heterozygous for the genetic defect, and one single change is sufficient to cause disease, hence the name "dominant." In disorders with autosomal recessive inheritance, both alleles (copies) of a defective gene on an autosomal chromosome pair are mutated (paternal and maternal copies). The pathogenic variants can be either the same (homozygous pathogenic variants) or two distinct pathogenic variants (compound heterozygous). Autosomal recessive conditions are more common when there is parental consanguinity (ie, related as second cousins or closer). The last form of inheritance is sex linked or linked to the sex chromosomes. X-linked recessive inheritance is the most common example. (See <a class="local">'Overview'</a> above and  <a class="medical medical_review" href="/z/d/html/103304.html" rel="external">"Genetic counseling: Family history interpretation and risk assessment"</a> and  <a class="medical medical_review" href="/z/d/html/2897.html" rel="external">"Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)"</a>.)</p><p class="headingAnchor" id="H866030577"><span class="h2">Single-gene disorders and the environment</span><span class="headingEndMark"> — </span>Genetic changes can be directly connected to alterations in environmental exposures such as the diet. A series of patients with multiple congenital malformations (cardiac and vertebral defects) underwent whole exome or whole genome sequencing to identify a possible genetic defect [<a href="#rid9">9</a>]. The affected individuals were found to have pathogenic loss-of-function variants in two genes (<em>HAAO</em>, encoding 3-hydroxyanthranilic acid 3,4-dioxygenase, and <em>KYNU</em>, encoding kynureninase) that are involved in the kynurenine pathway. This pathway results in the de novo synthesis of nicotinamide adenine dinucleotide (NAD) through catabolism of dietary tryptophan. In vitro activity of the truncated enzymes was low to absent, upstream metabolites were elevated, and downstream metabolites were reduced. In Haao-null or Kynu-null mice, supplementation of dietary niacin during gestation corrected the NAD deficiency, preventing intrauterine death and abnormal embryogenesis. (See  <a class="medical medical_review" href="/z/d/html/17039.html" rel="external">"Next-generation DNA sequencing (NGS): Principles and clinical applications", section on 'Diagnosis of complex diseases'</a>.)</p><p class="headingAnchor" id="H3863686733"><span class="h2">Genetic disorders with non-Mendelian patterns of inheritance</span><span class="headingEndMark"> — </span>Other genetic variations that can cause disorders include imprinting (gamete-specific gene silencing) disorders leading to differential expression of genetic material depending upon whether the gene or gene region is imprinted (eg, Beckwith-Wiedemann syndrome). (See  <a class="medical medical_review" href="/z/d/html/13555.html" rel="external">"Beckwith-Wiedemann syndrome"</a>.)</p><p class="headingAnchor" id="H1671907210"><span class="h1">TERATOGENS</span><span class="headingEndMark"> — </span>A teratogen is an agent that can cause abnormalities in the form or function of a developing fetus  (<a class="graphic graphic_table graphicRef73369" href="/z/d/graphic/73369.html" rel="external">table 1</a>). It acts by producing cell death, altering normal growth of tissues, or interfering with normal cellular differentiation or other morphologic processes. The consequences of these actions can be fetal loss, fetal growth restriction, congenital anomaly (eg, a limb reduction), or impaired neurologic performance (eg, altered neural connections in the central nervous system [CNS] in fetal alcohol syndrome).</p><p>Approximately 4 to 6 percent of congenital anomalies are caused by exposure to teratogens in the environment [<a href="#rid10">10</a>]. These include maternal illnesses (eg, diabetes mellitus or phenylketonuria [PKU]), infectious agents (eg, TORCH [<strong>T</strong>oxoplasmosis, <strong>O</strong>ther (syphilis, varicella-zoster, parvovirus B19), <strong>R</strong>ubella, <strong>C</strong>ytomegalovirus, and <strong>H</strong>erpes] infections), physical agents (eg, radiation or heat exposure), and drugs (eg, <a class="drug drug_pediatric" data-topicid="13090" href="/z/d/drug information/13090.html" rel="external">thalidomide</a>, antiseizure medications) and chemical agents (eg, mercury).</p><p>Response to the teratogenic agent is highly individualized and is influenced by multiple factors. These include maternal and fetal genotypes (genetic susceptibility), the dose of the agent, route of exposure, timing of exposure, and concurrent exposures or illnesses during gestation.</p><p class="headingAnchor" id="H2522579882"><span class="h2">Genetic susceptibility</span><span class="headingEndMark"> — </span>The genetic makeup of both the fetus and the mother determines the relative resistance or susceptibility to teratogenic agents. The degree of genetic susceptibility is separate from any specific genetic conditions that are known direct causes of congenital anomalies.</p><p>As an example, albeit an oversimplified one, fetuses with defects in folate metabolism (eg, methylenetetrahydrofolate reductase [<em>MTHFR</em>] gene pathogenic variants) appear to be at increased risk for structural malformations such as neural tube defects [<a href="#rid11">11</a>], cleft lip and palate, and cardiac malformations [<a href="#rid12">12</a>]. The risk of these malformations may be decreased by maternal supplementation with <a class="drug drug_pediatric" data-topicid="13322" href="/z/d/drug information/13322.html" rel="external">folic acid</a> in the preconceptional period and in early pregnancy [<a href="#rid13">13,14</a>]. Thus, a malformation such as an open neural tube defect may result from genetic susceptibility related to a combination of factors consisting of the presence of a fetal <em>MTHFR</em> gene defect and a state of inadequate maternal folate intake.</p><p>Another example is that some fetuses have low or deficient epoxide hydrolase activity that results in increased levels of teratogenic oxidative metabolites when they are exposed to antiseizure medications [<a href="#rid15">15</a>].</p><p>Finally, certain congenital anomalies may be seen with different frequencies across races or sexes. For example, postaxial polydactyly is more common among Black Americans (approximately 1 percent) than White Americans (approximately 0.1 percent) [<a href="#rid16">16</a>]. Neural tube defects are more common in White Americans than Black Americans. Pyloric stenosis and cleft lip are more common in males than females.</p><p>The genetic makeup of the mother and her state of health also play a role in teratogenesis. The production of a malformation is dependent upon the ability of a female to absorb and metabolize a teratogen. In addition, maternal medical disease states can act as teratogens. (See <a class="local">'Maternal illnesses'</a> below.)</p><p class="headingAnchor" id="H3847499768"><span class="h2">Route of exposure</span><span class="headingEndMark"> — </span>The route of exposure can also impact teratogenic effects. For example, the absorption and action of a drug is usually different if exposure occurs through the dermis versus systemic delivery. The systemic route may cause abnormalities, while the dermal delivery may not. As an example, topical <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a> applied to the skin is considered safe, but systemic fluconazole is potentially teratogenic [<a href="#rid17">17</a>]. Another example is topical use of retinoic acid versus oral/systemic use.</p><p class="headingAnchor" id="H3570750487"><span class="h2">Dose and duration of exposure</span><span class="headingEndMark"> — </span>The dose and duration of the embryo's exposure to a teratogen are also important. Most drugs exhibit threshold effects (ie, there is a dose below which the incidence of embryonic death, malformation, growth restriction, or functional impairment is not greater than for unexposed controls). Such thresholds are usually one to three orders of magnitude below the teratogenic dose of the drug [<a href="#rid18">18</a>].</p><p>When no human data are available, a dose teratogenic in animals that is less than 10-fold higher than the maximum human therapeutic dose suggests a high risk that the drug may be teratogenic in humans. A 100-fold difference between the animal teratogenic dose and the maximal human dose indicates a low risk of potential human teratogenicity. However, teratogenic agents may have different effects in different species. As an example, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, a <a class="drug drug_pediatric" data-topicid="13090" href="/z/d/drug information/13090.html" rel="external">thalidomide</a> analog, is not teratogenic in rabbits but is in humans [<a href="#rid19">19</a>]. By contrast, thalidomide is strongly teratogenic in both rabbits and humans but is not teratogenic in rats or mice [<a href="#rid20">20,21</a>]. <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">Aspirin</a> is not teratogenic in humans but is strongly teratogenic in other animals [<a href="#rid22">22</a>]. In addition, many drugs produce malformations in animals when given at 10 to 1000 times the normal dose administered to humans. Extrapolating teratogenic risk using these data is potentially problematic. As an example, high doses of <a class="drug drug_pediatric" data-topicid="12575" href="/z/d/drug information/12575.html" rel="external">meclizine</a> given to mice cause cleft palate due to appetite suppression, but force feeding the mice prevents the defect [<a href="#rid23">23</a>].</p><p>One teratogen may be more harmful in a single, large dose than in the same dose spread over several days, while another teratogen may be more harmful when an exposure is prolonged at a lower dose than if the same dose were given all at once. As an example, binge drinking of seven alcoholic beverages may be more harmful to the fetus than daily intake of only one drink for a week. Conversely, an occasional very high maternal blood glucose in an otherwise well-controlled diabetic mother is probably less harmful than a persistently moderately elevated blood glucose. (See  <a class="medical medical_review" href="/z/d/html/4798.html" rel="external">"Alcohol intake and pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/94859.html" rel="external">"Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management"</a>.)</p><p>Drug-drug interactions can also be important. Two drugs administered together may have synergistic effects, the drugs may act completely independently, or one drug may protect against the teratogenic effects of the other. As an example, the vitamin <a class="drug drug_pediatric" data-topicid="13322" href="/z/d/drug information/13322.html" rel="external">folic acid</a> may protect against the increased risk of open neural tube defects when taken by females who are taking antiseizure medications, such as <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">valproic acid</a> and <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">carbamazepine</a> [<a href="#rid24">24</a>]. However, valproic acid should not be used in pregnancy, if possible [<a href="#rid25">25</a>]. For specific interactions, use the <a class="external" href="/drug-interactions">drug interactions program</a> included within UpToDate. (See  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period"</a>.)</p><p class="headingAnchor" id="H3896141427"><span class="h2">Timing</span><span class="headingEndMark"> — </span>The pattern and type of malformation depend in part upon the time of exposure and/or the site of gene action. A brief review of human embryonic development indicates the system likely to be affected by a problem occurring at that time.</p><p>Fertilization is the first step and occurs within 24 hours of ovulation. Of note, embryonic age is counted from fertilization (conception) and starts two weeks after gestational age, which is counted from the first day of the last menstrual period. The following are other important milestones in development  (<a class="graphic graphic_figure graphicRef65456" href="/z/d/graphic/65456.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Preimplantation and implantation on days 5 to 11</p><p class="bulletIndent1"><span class="glyph">●</span>Differentiation into three germ layers (ectoderm, mesoderm, and endoderm) by day 16</p><p class="bulletIndent1"><span class="glyph">●</span>Formation of the neural plate by day 19</p><p class="bulletIndent1"><span class="glyph">●</span>Closure of the neural tube by day 27</p><p class="bulletIndent1"><span class="glyph">●</span>Appearance of limb buds by day 30</p><p class="bulletIndent1"><span class="glyph">●</span>Formation of the branchial arches, clefts, pouches, and optic vesicle between weeks 4 and 5</p><p class="bulletIndent1"><span class="glyph">●</span>Formation of the mature heart and kidneys by weeks 5 to 7</p><p class="bulletIndent1"><span class="glyph">●</span>Achievement of mature limb architecture by week 8</p><p class="bulletIndent1"><span class="glyph">●</span>Sexual differentiation of the internal and external genitalia between weeks 7 to 10</p><p class="bulletIndent1"><span class="glyph">●</span>Rotation of the intestines and return into the abdominal cavity in week 10</p><p></p><p>A significant exposure that occurs during the first 10 to 14 days after fertilization may result in cell death. If enough cells die, spontaneous abortion may occur (see  <a class="medical medical_review" href="/z/d/html/5439.html" rel="external">"Pregnancy loss (miscarriage): Terminology, risk factors, and etiology"</a>). If only a few cells are damaged, then their roles may be compensated by other cells. This is known as the all-or-none theory. An example is an early and significant exposure to radiation, which usually results in either pregnancy loss or no abnormalities.</p><p>The embryo is most vulnerable to teratogenic insults since organogenesis is occurring during the embryonic period of development. The embryonic period in humans can be defined as from fertilization until the end of the 10<sup>th</sup> week of gestation (8<sup>th</sup> week postconception) [<a href="#rid26">26</a>].</p><p>During the fetal period, teratogens can cause cell death, retardation of cell growth, or inhibition of normal differentiation. This may result in fetal growth restriction or disorders of the CNS that may not be apparent at birth. The eyes, genitalia, CNS, and hematopoietic systems continue to develop during the fetal period and remain susceptible to teratogenic insults.</p><p>As an example, the risks associated with angiotensin-converting enzyme (ACE) inhibitor exposure, a widely used medicine to treat hypertension, are significant during the second and third trimesters due to blockade of conversion of angiotensinogen I to angiotensin II in the developing fetal kidney. This exposure results in hypotension, renal tubular dysplasia, anuria/oligohydramnios, growth restriction, and calvaria defects. However, these drugs can cause other defects, such congenital heart defects, during the first trimester [<a href="#rid27">27</a>].</p><p><a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">Misoprostol</a>, a prostaglandin E1 analog, can cause severe vascular disruptions in the first trimester (ie, terminal limb defects, Moebius syndrome). It has also been widely used to induce abortions in the first and second trimesters. However, this drug is safe to use during delivery for uterine cervix ripening and to induce labor [<a href="#rid28">28</a>].</p><p>Some teratogens act within a narrow window. As an example, the teratogenic effect of <a class="drug drug_pediatric" data-topicid="13090" href="/z/d/drug information/13090.html" rel="external">thalidomide</a> for limb defects is limited to 21 to 36 days postconception, when limb bud development begins.</p><p class="headingAnchor" id="H2284149801"><span class="h2">Mechanisms of teratogenesis</span><span class="headingEndMark"> — </span>Teratogenesis is thought to occur after fertilization and results from many diverse mechanisms. These include cell death (eg, radiation); blocking of metabolic processes (eg, thioureas, iodides); alterations in cellular growth and proliferation, migration, and apoptosis (eg, alcohol exposure, fetal alcohol spectrum disorder); and interactions between cells or between cells and tissues.</p><p>Exposure prior to conception may theoretically cause genetic pathogenic variants, a process known as toxic mutagenesis, although this is a controversial topic. The timing of this process differs in males and females. In females, deoxyribonucleic acid (DNA) replication occurs during oogenesis in the fetus, many years before ovulation. In contrast, continuing spermatogenesis makes males susceptible to pathogenic variants throughout their reproductive life. Examples include the potential effects of ionizing radiation on spermatogenesis [<a href="#rid29">29</a>] and potential effects of chemotherapy drugs in the reproductive system [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H2638135791"><span class="h2">Specific teratogens</span><span class="headingEndMark"> — </span>Numerous teratogens in the environment can lead to congenital anomalies. Common agents are listed below and in the table  (<a class="graphic graphic_table graphicRef73369" href="/z/d/graphic/73369.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H4241957187"><span class="h3">Infectious agents</span><span class="headingEndMark"> — </span>Exposure to infectious agents can result in a variety of problems in the fetus and neonate, including malformations, congenital infection, short- and long-term disability, and death. The pathogenesis of the fetal defects is usually direct invasion of fetal tissues leading to damage from inflammation and cell death. Agents known to be toxic to the fetus or embryo are toxoplasmosis, rubella, cytomegalovirus, herpes, and syphilis (the so-called TORCH infections), as well as varicella, parvovirus B19, Zika virus, and lymphocytic choriomeningitis virus (LCMV). (See  <a class="medical medical_review" href="/z/d/html/6011.html" rel="external">"Overview of TORCH infections"</a> and  <a class="medical medical_review" href="/z/d/html/4794.html" rel="external">"Syphilis in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/8331.html" rel="external">"Varicella-zoster virus infection in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/8281.html" rel="external">"Parvovirus B19 infection during pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/8312.html" rel="external">"Rubella in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/13972.html" rel="external">"Prenatal evaluation of women with HIV in resource-rich settings"</a> and  <a class="medical medical_review" href="/z/d/html/5983.html" rel="external">"Viral meningitis in children: Clinical features and diagnosis", section on 'Other viruses'</a> and  <a class="medical medical_review" href="/z/d/html/15870.html" rel="external">"Seasonal influenza and pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/107211.html" rel="external">"Zika virus infection: Evaluation and management of pregnant patients"</a>.)</p><p>Nonspecific sonographic signs suggestive of fetal infection include:</p><p class="bulletIndent1"><span class="glyph">●</span>Microcephaly</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebral or hepatic calcifications</p><p class="bulletIndent1"><span class="glyph">●</span>Intrauterine growth restriction</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatosplenomegaly</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac malformations, limb hypoplasia, hydrocephalus</p><p class="bulletIndent1"><span class="glyph">●</span>Hydrops</p><p></p><p>Congenital anomalies associated with disorders of movement and muscle tone, chorioretinitis or cataracts, hearing impairment, hepatosplenomegaly, skin rash, thrombocytopenia, jaundice, or low birth weight are suggestive of congenital infection.</p><p>Fever associated with infection also can be teratogenic. (See <a class="local">'Physical agents'</a> below.)</p><p class="headingAnchor" id="H1871409813"><span class="h3">Maternal illnesses</span><span class="headingEndMark"> — </span>Several maternal illnesses are associated with birth defects. The mechanism is diffusion of a metabolite or antibody across the placenta that is toxic to the fetus.</p><p class="bulletIndent1"><span class="glyph">●</span>Insulin-dependent diabetes mellitus is associated with a two- to threefold increase in risk of congenital anomalies, including congenital heart disease, cleft palate, colobomas, and spina bifida, and, less commonly, caudal regression and focal femoral hypoplasia. (See  <a class="medical medical_review" href="/z/d/html/5058.html" rel="external">"Infants of mothers with diabetes (IMD)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maternal phenylketonuria (PKU) if not diet controlled is associated with microcephaly, intellectual disability, and congenital heart disease. (See  <a class="medical medical_review" href="/z/d/html/2919.html" rel="external">"Overview of phenylketonuria"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Androgen-producing tumors of the adrenal glands or ovaries can produce virilization of female fetuses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maternal antibodies present in autoimmune disorders can cross the placenta and cause toxicity in the fetus. Examples include myasthenia gravis leading to transient neonatal myasthenia, maternal Grave disease causing fetal and neonatal thyrotoxicosis, immune thrombocytopenia (ITP) resulting in fetal and neonatal thrombocytopenia, and systemic lupus erythematosus causing fetal heart block. (See  <a class="medical medical_review" href="/z/d/html/5157.html" rel="external">"Overview of the treatment of myasthenia gravis"</a> and  <a class="medical medical_review" href="/z/d/html/7884.html" rel="external">"Hyperthyroidism during pregnancy: Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/6681.html" rel="external">"Thrombocytopenia in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/4679.html" rel="external">"Pregnancy in women with systemic lupus erythematosus"</a>.)</p><p></p><p>Maternal obesity and hypertensive disorders (including preeclampsia and preexisting hypertension) [<a href="#rid31">31</a>] are also associated with an increased risk of certain types of congenital anomalies. The mechanism is unknown, but one hypothesis is that these disorders lead to aberrant early implantation or impair early blood supply to the fetus. (See  <a class="medical medical_review" href="/z/d/html/433.html" rel="external">"Obesity in pregnancy: Complications and maternal management", section on 'Congenital anomalies'</a>.)</p><p class="headingAnchor" id="H1653489171"><span class="h3">Physical agents</span><span class="headingEndMark"> — </span>Physical agents, such as heat and radiation, have been implicated in the pathogenesis of congenital anomalies. Heat exposure may be due to the use of a hot tub or sauna or even maternal fever. Elevation of maternal core temperature more than 1.5°C in the first trimester of pregnancy for at least 24 hours may be associated with an increased risk of neural tube defects [<a href="#rid32">32-34</a>]. Other clinical findings associated with high maternal temperature include microcephaly, intellectual disability, hypertonia, hypotonia, and seizures. (See  <a class="medical medical_review" href="/z/d/html/4453.html" rel="external">"Intrapartum fever", section on 'Consequences'</a>.)</p><p>Excessive exposure to ionizing radiation has the potential to produce fetal death, growth disturbances, somatic abnormalities, mutations, chromosome fragmentation, and malignancies. In general, toxic levels are not achieved with diagnostic imaging. However, knowledge of a pregnancy should, in most circumstances, result in a reappraisal of the necessity for and mode of imaging. (See  <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients"</a> and  <a class="medical medical_review" href="/z/d/html/14613.html" rel="external">"Radiation-related risks of imaging"</a>.)</p><p class="headingAnchor" id="H525523356"><span class="h3">Drug exposure</span><span class="headingEndMark"> — </span>Maternal drug ingestion, including prescription and over-the-counter medications as well as recreational drugs, can also cause adverse fetal and neonatal outcomes. However, it can be extremely difficult to determine whether a particular substance is teratogenic. In addition, the timing of exposure during pregnancy can affect the teratogenicity of a drug. A partial list of additional known teratogens is provided in the table  (<a class="graphic graphic_table graphicRef73369" href="/z/d/graphic/73369.html" rel="external">table 1</a>).</p><p>The US Food and Drug Administration (FDA) requires that all prescription drugs be tested in animal models, usually one rodent and one nonrodent model. Testing establishes both the lowest observed adverse effect level (LOAEL) and the no observed adverse effect level (NOAEL). If the human exposure level is 100 times lower than the NOAEL, adverse effects in humans are considered unlikely. However, results from animal models may not always apply to humans (see <a class="local">'Dose and duration of exposure'</a> above). A study of drugs approved by the US FDA from 2000 to 2010 found that the teratogenic risk in human pregnancy was "undetermined" for 98 percent of the drugs approved for human use [<a href="#rid35">35</a>].</p><p>Due to the limitations of drug testing, data regarding the association of drugs or chemicals and congenital anomalies occurring at the time of birth come primarily from case reports of exposed patients. However, these also do not always establish teratogenicity and often need validation by epidemiologic studies. Two promising approaches to providing somewhat better information are prospectively collected exposure data from teratogen information agencies and large-scale birth defects registries [<a href="#rid36">36</a>]. Postmarketing drug registries are also used to monitor for teratogenicity, but they rely on active participation of clinicians and pregnant patients and as such are not comprehensive in their surveillance. As previously discussed, some of the drugs can be potentially teratogenic during specific times of fetal development but be innocuous otherwise. (See <a class="local">'Timing'</a> above.)</p><p>In 2015, the US FDA switched from labeling prescription drugs for use during pregnancy with one of five categories (A, B, C, D, or X), ranging from drugs posing no risk to the fetus to those known to be teratogenic, to the Pregnancy and Lactation Labeling Rule (PLLR or final rule) [<a href="#rid37">37</a>]. The PLLR "requires that the labeling include a summary of the risks of using a drug during pregnancy and lactation, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy and lactation."</p><p>Some common teratogenic medications include:</p><p class="bulletIndent1"><span class="glyph">●</span>Angiotensin-converting enzyme (ACE) inhibitors (see  <a class="medical medical_review" href="/z/d/html/4789.html" rel="external">"Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy"</a> and <a class="local">'Timing'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antiseizure medications [<a href="#rid38">38</a>] (see  <a class="medical medical_review" href="/z/d/html/2218.html" rel="external">"Risks associated with epilepsy during pregnancy and the postpartum period"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antineoplastic agents (see  <a class="medical medical_review" href="/z/d/html/786.html" rel="external">"Gestational breast cancer: Epidemiology and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4692.html" rel="external">"Management of classic Hodgkin lymphoma during pregnancy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13090" href="/z/d/drug information/13090.html" rel="external">Thalidomide</a>, <a class="drug drug_pediatric" data-topicid="12599" href="/z/d/drug information/12599.html" rel="external">methylene blue</a>, <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>, <a class="drug drug_pediatric" data-topicid="12685" href="/z/d/drug information/12685.html" rel="external">penicillamine</a>, <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a>, and <a class="drug drug_pediatric" data-topicid="12559" href="/z/d/drug information/12559.html" rel="external">lithium</a></p><p></p><p>Additional known teratogens include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13322" href="/z/d/drug information/13322.html" rel="external">Folic acid</a> antagonists (eg, <a class="drug drug_pediatric" data-topicid="12865" href="/z/d/drug information/12865.html" rel="external">trimethoprim</a>, <a class="drug drug_pediatric" data-topicid="12859" href="/z/d/drug information/12859.html" rel="external">triamterene</a>, <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">carbamazepine</a>, <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a>, <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a>, <a class="drug drug_pediatric" data-topicid="12727" href="/z/d/drug information/12727.html" rel="external">primidone</a>, <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">methotrexate</a>) increase the risk of neural tube defects and possibly cardiovascular defects, oral clefts, and urinary tract defects [<a href="#rid24">24,39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral <a class="drug drug_pediatric" data-topicid="13395" href="/z/d/drug information/13395.html" rel="external">isotretinoin</a>, used to treat severe acne, is associated with ear anomalies (microtia with or without atresia of the ear canal), CNS malformations, hydrocephalus, neuronal brain migration defects, cerebellum abnormalities, severe intellectual disability, seizures, optic nerve/retinal abnormalities, conotruncal heart defects, thymic defects, and dysmorphic features [<a href="#rid40">40,41</a>]. (See  <a class="medical medical_review" href="/z/d/html/42.html" rel="external">"Acne vulgaris: Overview of management", section on 'Pregnant individuals'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The widely used cholesterol-lowering agents, such as statins (HMG-CoA reductase inhibitors) are completely contraindicated during pregnancy because they may cause severe congenital anomalies due to disruption of cholesterol biosynthesis, which is important in cell membrane morphogenesis. Reported congenital anomalies include limb malformations, congenital heart disease, and CNS abnormalities [<a href="#rid42">42,43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infants of mothers who consumed substantial quantities of alcohol during pregnancy [<a href="#rid44">44</a>] can have a neurobehavioral disorder associated with prenatal alcohol exposure (ND-PAE), alcohol-related birth defects (ARBD), fetal alcohol syndrome, or they may be normal  (<a class="graphic graphic_table graphicRef95001" href="/z/d/graphic/95001.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/4798.html" rel="external">"Alcohol intake and pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/4799.html" rel="external">"Substance use during pregnancy: Screening and prenatal care"</a> and  <a class="medical medical_review" href="/z/d/html/14381.html" rel="external">"Fetal alcohol spectrum disorder: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cigarette smoking is associated with poor fetal growth mostly due to effects on the placenta [<a href="#rid45">45,46</a>]. Smoking is also linked to increased limb deficiencies in epidemiologic studies [<a href="#rid47">47</a>]. The failure or disruption in formation of limbs or digits may result from vasoactive effects of cigarette compounds on blood vessels. Prenatal exposure can also lead to impaired function of the endocrine, reproductive, respiratory, cardiovascular, and neurologic systems [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/z/d/html/4803.html" rel="external">"Cigarette and tobacco products in pregnancy: Impact on pregnancy and the neonate"</a>.)</p><p></p><p class="headingAnchor" id="H846592413"><span class="h3">Chemical agents</span><span class="headingEndMark"> — </span>Chemical agents that can act as teratogens include lead and mercury.</p><p>High plasma lead levels are associated with adverse neurobehavioral effects in infants and children. Intrauterine exposure may have similar consequences [<a href="#rid49">49</a>]. Studies of potential associations between parental lead exposure and congenital malformations in offspring have not demonstrated a consistent increase in risk or pattern of defects, but often lack biologic indices of exposure at developmentally significant times [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/111468.html" rel="external">"Occupational and environmental risks to reproduction in females: Specific exposures and impact", section on 'Lead'</a>.)</p><p>Methylmercury exposure, primarily through ingestion of contaminated fish, can cause severe CNS damage [<a href="#rid51">51</a>], as well as milder intellectual, motor, and psychosocial impairment [<a href="#rid52">52-54</a>]. Some limitations on fish intake during pregnancy are recommended. (See  <a class="medical medical_review" href="/z/d/html/431.html" rel="external">"Fish consumption and marine omega-3 fatty acid supplementation in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/130920.html" rel="external">"Nutrition in pregnancy: Assessment and counseling", section on 'Counseling'</a>.)</p><p class="headingAnchor" id="H3671500450"><span class="h2">Resources</span><span class="headingEndMark"> — </span>Several resources are available for information on possible teratogenic exposure. These include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Freprotox.org%2F&amp;token=Ryuc2NABJGKCQZO0cGQLQ%2BlIiapLy0sf7zMh%2FrkID0g%3D&amp;TOPIC_ID=110900" target="_blank">Reproductive Toxicology Center</a></p><p class="bulletIndent1">REPROTOX</p><p class="bulletIndent1">Columbia Hospital for Women Medical Center</p><p class="bulletIndent1">Washington, DC</p><p class="bulletIndent1">703-203-6040</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdeohs.washington.edu%2Fteris%2F&amp;token=RkqhEFptHofdd7816QG%2B7MPc6vbj2UCuaY0DDLsFjBB6lpH7znzLPqgN%2B06w6UrL&amp;TOPIC_ID=110900" target="_blank">Teratogen Information System</a></p><p class="bulletIndent1">TERIS and Shepard's Catalog of Teratogenic Agents</p><p class="bulletIndent1">Seattle, WA</p><p class="bulletIndent1">206-543-2465</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fconsumers%2Fpregnancy-exposure-registries%2Flist-pregnancy-exposure-registries&amp;token=8RYIFfyLhIBYEqeX7m6uPLinVNkXlWi8yEx6yLCkswRePwXsvf4SDZWjWrU3SZXg7pQs3USMF7LKt%2FCUd1J3tbsTc7qFAquIPgOHZ21VQKk%3D&amp;TOPIC_ID=110900" target="_blank">Pregnancy Exposure Registries</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmothertobaby.org%2F&amp;token=cjWcuFd4xzPwN3syululi0BZIoY3uIDSoxeE%2FFYkZXAng4095mMxYKel1K7syBN0&amp;TOPIC_ID=110900" target="_blank">Organization of Teratology Information Specialists (OTIS)</a></p><p class="bulletIndent1">877-311-8972</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbirthdefectsresearch.org%2Fprimer%2F&amp;token=uGiqmgDIlmXwy5WtFd5BFadFJRFIFQbRmMVvJXbgqyhdfYCosOUJKRHguI1WXBCHrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=110900" target="_blank">The Teratology Society</a></p><p class="bulletIndent1">The Teratology Society publishes a free teratology primer</p><p></p><p class="headingAnchor" id="H1336114441"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/82980.html" rel="external">"Patient education: Newborn appearance (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H293794729"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and etiology</strong> – A congenital anomaly refers to an anatomic structural anomaly present at birth. These defects can be caused by genetic abnormalities and/or environmental exposures (teratogens), although the underlying etiology is often unknown. (See <a class="local">'Introduction'</a> above and <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of congenital anomalies and patterns of malformations</strong> – Specific terms are used to describe congenital anomalies  (<a class="graphic graphic_table graphicRef57394" href="/z/d/graphic/57394.html" rel="external">table 3</a>). In addition, multiple malformations are often grouped in a recognizable pattern  (<a class="graphic graphic_table graphicRef75281" href="/z/d/graphic/75281.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/110898.html" rel="external">"Congenital anomalies: Epidemiology, types, and patterns", section on 'Types and patterns of defects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic causes</strong> – Genetic causes of congenital anomalies include chromosomal disorders, single-gene disorders, somatic mutation/mosaicism, and disorders that result from the interaction of multiple genes and environmental factors (multifactorial disorders). (See <a class="local">'Genetic abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Environmental causes</strong> – Environmental causes of congenital anomalies include multiple gestation pregnancy and teratogens. A teratogen is an agent that can cause abnormalities in the form or function of a developing fetus  (<a class="graphic graphic_table graphicRef73369" href="/z/d/graphic/73369.html" rel="external">table 1</a>). The pattern and type of malformation depend in part upon the time of exposure and/or the site of gene action. (See <a class="local">'Teratogens'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Feldkamp ML, Carey JC, Byrne JLB, et al. Etiology and clinical presentation of birth defects: population based study. BMJ 2017; 357:j2249.</a></li><li class="breakAll">Human malformations and related anomalies. In: Oxford monographs on medical genetics, Stevenson RE, Hall JG, Goodman RM (Eds), Oxford University Press, New York 1993. Vol 1.</li><li><a class="nounderline abstract_t">van Bokhoven H, Hamel BC, Bamshad M, et al. p63 Gene mutations in eec syndrome, limb-mammary syndrome, and isolated split hand-split foot malformation suggest a genotype-phenotype correlation. Am J Hum Genet 2001; 69:481.</a></li><li><a class="nounderline abstract_t">Maas SM, de Jong TP, Buss P, Hennekam RC. EEC syndrome and genitourinary anomalies: an update. Am J Med Genet 1996; 63:472.</a></li><li><a class="nounderline abstract_t">Shaheen R, Faqeih E, Sunker A, et al. Recessive mutations in DOCK6, encoding the guanidine nucleotide exchange factor DOCK6, lead to abnormal actin cytoskeleton organization and Adams-Oliver syndrome. Am J Hum Genet 2011; 89:328.</a></li><li><a class="nounderline abstract_t">Goltz RW, Henderson RR, Hitch JM, Ott JE. Focal dermal hypoplasia syndrome. A review of the literature and report of two cases. Arch Dermatol 1970; 101:1.</a></li><li><a class="nounderline abstract_t">Grzeschik KH, Bornholdt D, Oeffner F, et al. Deficiency of PORCN, a regulator of Wnt signaling, is associated with focal dermal hypoplasia. Nat Genet 2007; 39:833.</a></li><li><a class="nounderline abstract_t">Hook EB. Chromosome abnormalities and spontaneous fetal death following amniocentesis: further data and associations with maternal age. Am J Hum Genet 1983; 35:110.</a></li><li><a class="nounderline abstract_t">Shi H, Enriquez A, Rapadas M, et al. NAD Deficiency, Congenital Malformations, and Niacin Supplementation. N Engl J Med 2017; 377:544.</a></li><li class="breakAll">Roger E. Stevenson. The Genetic Basis of Human Anomalies. In: Human Malformations and Related Anomalies, Roger E. Stevenson, Judith G. Hall, Richard M. Goodman (Eds), Oxford University Press, Oxford 1993. Vol I.</li><li><a class="nounderline abstract_t">Wenstrom KD, Johanning GL, Owen J, et al. Role of amniotic fluid homocysteine level and of fetal 5, 10-methylenetetrahydrafolate reductase genotype in the etiology of neural tube defects. Am J Med Genet 2000; 90:12.</a></li><li><a class="nounderline abstract_t">Wenstrom KD, Johanning GL, Johnston KE, DuBard M. Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations. Am J Obstet Gynecol 2001; 184:806.</a></li><li><a class="nounderline abstract_t">Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 1991; 338:131.</a></li><li><a class="nounderline abstract_t">Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327:1832.</a></li><li><a class="nounderline abstract_t">Finnell RH, Buehler BA, Kerr BM, et al. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology 1992; 42:25.</a></li><li><a class="nounderline abstract_t">Holmes LB, Nasri H, Hunt AT, et al. Polydactyly, postaxial, type B. Birth Defects Res 2018; 110:134.</a></li><li><a class="nounderline abstract_t">King CT, Rogers PD, Cleary JD, Chapman SW. Antifungal therapy during pregnancy. Clin Infect Dis 1998; 27:1151.</a></li><li><a class="nounderline abstract_t">Beckman DA, Brent RL. Mechanism of known environmental teratogens: drugs and chemicals. Clin Perinatol 1986; 13:649.</a></li><li><a class="nounderline abstract_t">Christian MS, Laskin OL, Sharper V, et al. Evaluation of the developmental toxicity of lenalidomide in rabbits. Birth Defects Res B Dev Reprod Toxicol 2007; 80:188.</a></li><li class="breakAll">S5(R3) Detection of reproductive and developmental toxicity for human pharmaceuticals: Guidance for industry. US Department of Health and Human Services, May 2021. https://www.fda.gov/media/148475/download (Accessed on September 26, 2022).</li><li><a class="nounderline abstract_t">Vargesson N. Thalidomide embryopathy: An enigmatic challenge. ISRN Devel Biol 2013; :1.</a></li><li><a class="nounderline abstract_t">Robertson RT, Allen HL, Bokelman DL. Aspirin: teratogenic evaluation in the dog. Teratology 1979; 20:313.</a></li><li><a class="nounderline abstract_t">Brent RL. The complexities of solving the problem of human malformations. Clin Perinatol 1986; 13:491.</a></li><li><a class="nounderline abstract_t">Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343:1608.</a></li><li><a class="nounderline abstract_t">Harden CL, Meador KJ, Pennell PB, et al. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009; 50:1237.</a></li><li><a class="nounderline abstract_t">Polifka JE, Friedman JM. Medical genetics: 1. Clinical teratology in the age of genomics. CMAJ 2002; 167:265.</a></li><li><a class="nounderline abstract_t">Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354:2443.</a></li><li><a class="nounderline abstract_t">Tang J, Kapp N, Dragoman M, de Souza JP. WHO recommendations for misoprostol use for obstetric and gynecologic indications. Int J Gynaecol Obstet 2013; 121:186.</a></li><li><a class="nounderline abstract_t">Xu G, Intano GW, McCarrey JR, et al. Recovery of a low mutant frequency after ionizing radiation-induced mutagenesis during spermatogenesis. Mutat Res 2008; 654:150.</a></li><li><a class="nounderline abstract_t">Povirk LF, Shuker DE. DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res 1994; 318:205.</a></li><li><a class="nounderline abstract_t">Weber KA, Mayo JA, Carmichael SL, et al. Occurrence of Selected Structural Birth Defects Among Women With Preeclampsia and Other Hypertensive Disorders. Am J Epidemiol 2018; 187:668.</a></li><li><a class="nounderline abstract_t">Milunsky A, Ulcickas M, Rothman KJ, et al. Maternal heat exposure and neural tube defects. JAMA 1992; 268:882.</a></li><li><a class="nounderline abstract_t">Chambers CD, Johnson KA, Dick LM, et al. Maternal fever and birth outcome: a prospective study. Teratology 1998; 58:251.</a></li><li><a class="nounderline abstract_t">Pleet H, Graham JM Jr, Smith DW. Central nervous system and facial defects associated with maternal hyperthermia at four to 14 weeks' gestation. Pediatrics 1981; 67:785.</a></li><li><a class="nounderline abstract_t">Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet 2011; 157C:175.</a></li><li><a class="nounderline abstract_t">Lisi A, Botto LD, Robert-Gnansia E, et al. Surveillance of adverse fetal effects of medications (SAFE-Med): findings from the international Clearinghouse of birth defects surveillance and research. Reprod Toxicol 2010; 29:433.</a></li><li class="breakAll">FDA Pregnancy and Lactation Labeling Rule. https://www.federalregister.gov/documents/2014/12/04/2014-28241/content-and-format-of-labeling-for-human-prescription-drug-and-biological-products-requirements-for.</li><li><a class="nounderline abstract_t">Bromley RL, Weston J, Marson AG. Maternal Use of Antiepileptic Agents During Pregnancy and Major Congenital Malformations in Children. JAMA 2017; 318:1700.</a></li><li><a class="nounderline abstract_t">Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001; 153:961.</a></li><li><a class="nounderline abstract_t">Hanson N, Leachman S. Safety issues in isotretinoin therapy. Semin Cutan Med Surg 2001; 20:166.</a></li><li><a class="nounderline abstract_t">Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998; 338:1128.</a></li><li><a class="nounderline abstract_t">Petersen EE, Mitchell AA, Carey JC, et al. Maternal exposure to statins and risk for birth defects: a case-series approach. Am J Med Genet A 2008; 146A:2701.</a></li><li><a class="nounderline abstract_t">Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol 2008; 26:175.</a></li><li><a class="nounderline abstract_t">Feldman HS, Jones KL, Lindsay S, et al. Prenatal alcohol exposure patterns and alcohol-related birth defects and growth deficiencies: a prospective study. Alcohol Clin Exp Res 2012; 36:670.</a></li><li><a class="nounderline abstract_t">Bailey RR. The effect of maternal smoking on the infant birth weight. N Z Med J 1970; 71:293.</a></li><li><a class="nounderline abstract_t">Windham GC, Eaton A, Hopkins B. Evidence for an association between environmental tobacco smoke exposure and birthweight: a meta-analysis and new data. Paediatr Perinat Epidemiol 1999; 13:35.</a></li><li><a class="nounderline abstract_t">Caspers KM, Romitti PA, Lin S, et al. Maternal periconceptional exposure to cigarette smoking and congenital limb deficiencies. Paediatr Perinat Epidemiol 2013; 27:509.</a></li><li><a class="nounderline abstract_t">Holbrook BD. The effects of nicotine on human fetal development. Birth Defects Res C Embryo Today 2016; 108:181.</a></li><li><a class="nounderline abstract_t">Gomaa A, Hu H, Bellinger D, et al. Maternal bone lead as an independent risk factor for fetal neurotoxicity: a prospective study. Pediatrics 2002; 110:110.</a></li><li><a class="nounderline abstract_t">Rischitelli G, Nygren P, Bougatsos C, et al. Screening for elevated lead levels in childhood and pregnancy: an updated summary of evidence for the US Preventive Services Task Force. Pediatrics 2006; 118:e1867.</a></li><li><a class="nounderline abstract_t">Harada M. Congenital Minamata disease: intrauterine methylmercury poisoning. Teratology 1978; 18:285.</a></li><li><a class="nounderline abstract_t">Crump KS, Kjellström T, Shipp AM, et al. Influence of prenatal mercury exposure upon scholastic and psychological test performance: benchmark analysis of a New Zealand cohort. Risk Anal 1998; 18:701.</a></li><li><a class="nounderline abstract_t">Grandjean P, Weihe P, White RF, et al. Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury. Neurotoxicol Teratol 1997; 19:417.</a></li><li class="breakAll">Kjellstrom T, Kennedy P, Wallis S, et al. Physical and mental development of children with prenatal exposure to mercury from fish. Stage 1 and stage 2 results at ages 4 and six. National Swedish Envirnomental Board Reports #3080 (1980) and 3642 (1986).</li></ol></div><div id="topicVersionRevision">Topic 110900 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28559234" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Etiology and clinical presentation of birth defects: population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28559234" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Etiology and clinical presentation of birth defects: population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11462173" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : p63 Gene mutations in eec syndrome, limb-mammary syndrome, and isolated split hand-split foot malformation suggest a genotype-phenotype correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8737655" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : EEC syndrome and genitourinary anomalies: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21820096" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Recessive mutations in DOCK6, encoding the guanidine nucleotide exchange factor DOCK6, lead to abnormal actin cytoskeleton organization and Adams-Oliver syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5416790" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Focal dermal hypoplasia syndrome. A review of the literature and report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17546031" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Deficiency of PORCN, a regulator of Wnt signaling, is associated with focal dermal hypoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6218752" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chromosome abnormalities and spontaneous fetal death following amniocentesis: further data and associations with maternal age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28792876" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : NAD Deficiency, Congenital Malformations, and Niacin Supplementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28792876" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : NAD Deficiency, Congenital Malformations, and Niacin Supplementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10602111" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Role of amniotic fluid homocysteine level and of fetal 5, 10-methylenetetrahydrafolate reductase genotype in the etiology of neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11303187" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1677062" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1307234" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1574173" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29377639" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Polydactyly, postaxial, type B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9827262" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Antifungal therapy during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3533369" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mechanism of known environmental teratogens: drugs and chemicals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17570132" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evaluation of the developmental toxicity of lenalidomide in rabbits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17570132" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Evaluation of the developmental toxicity of lenalidomide in rabbits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Thalidomide embryopathy: An enigmatic challenge</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/524304" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Aspirin: teratogenic evaluation in the dog.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3533363" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The complexities of solving the problem of human malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11096168" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Folic acid antagonists during pregnancy and the risk of birth defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19507301" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12186175" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Medical genetics: 1. Clinical teratology in the age of genomics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16760444" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Major congenital malformations after first-trimester exposure to ACE inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23433680" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : WHO recommendations for misoprostol use for obstetric and gynecologic indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18582597" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Recovery of a low mutant frequency after ionizing radiation-induced mutagenesis during spermatogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7527485" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : DNA damage and mutagenesis induced by nitrogen mustards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020134" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Occurrence of Selected Structural Birth Defects Among Women With Preeclampsia and Other Hypertensive Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1640616" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Maternal heat exposure and neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9894674" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Maternal fever and birth outcome: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7232042" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Central nervous system and facial defects associated with maternal hyperthermia at four to 14 weeks' gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21766440" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Evolving knowledge of the teratogenicity of medications in human pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20347959" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Surveillance of adverse fetal effects of medications (SAFE-Med): findings from the international Clearinghouse of birth defects surveillance and research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20347959" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Surveillance of adverse fetal effects of medications (SAFE-Med): findings from the international Clearinghouse of birth defects surveillance and research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29114815" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Maternal Use of Antiepileptic Agents During Pregnancy and Major Congenital Malformations in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11384952" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Neural tube defects in relation to use of folic acid antagonists during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11594672" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Safety issues in isotretinoin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9545362" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Drugs in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18792975" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Maternal exposure to statins and risk for birth defects: a case-series approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18640262" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22250768" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prenatal alcohol exposure patterns and alcohol-related birth defects and growth deficiencies: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5270976" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The effect of maternal smoking on the infant birth weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9987784" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Evidence for an association between environmental tobacco smoke exposure and birthweight: a meta-analysis and new data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24134526" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Maternal periconceptional exposure to cigarette smoking and congenital limb deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27297020" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The effects of nicotine on human fetal development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12093955" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Maternal bone lead as an independent risk factor for fetal neurotoxicity: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17142507" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Screening for elevated lead levels in childhood and pregnancy: an updated summary of evidence for the US Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/362594" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Congenital Minamata disease: intrauterine methylmercury poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9972579" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Influence of prenatal mercury exposure upon scholastic and psychological test performance: benchmark analysis of a New Zealand cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9392777" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
